Quest Diagnostics Incorporated (DGX)
Market Cap | 15.23B |
Revenue (ttm) | 9.25B |
Net Income (ttm) | 854.00M |
Shares Out | 110.71M |
EPS (ttm) | 7.49 |
PE Ratio | 18.42 |
Forward PE | 15.61 |
Dividend | $3.00 (2.18%) |
Ex-Dividend Date | Apr 5, 2024 |
Volume | 1,531,800 |
Open | 136.00 |
Previous Close | 136.70 |
Day's Range | 134.95 - 138.32 |
52-Week Range | 119.59 - 147.97 |
Beta | 0.89 |
Analysts | Buy |
Price Target | 148.00 (+7.6%) |
Earnings Date | Apr 23, 2024 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, govern... [Read more]
Financial Performance
In 2023, DGX's revenue was $9.25 billion, a decrease of -6.38% compared to the previous year's $9.88 billion. Earnings were $854.00 million, a decrease of -9.73%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $148.0, which is an increase of 7.60% from the latest price.
News
Quest Diagnostics raises 2024 profit and revenue forecast on strong demand
Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023 Fu...
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health SECAUCUS, N.J...
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs SECAUCUS, N.J. , April 2, 2024 /PRNewswire/ -- Quest Diagnostic...
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality e...
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial resul...
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Fin...
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impac...
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
– Roche led the financing alongside existing and new investors – – The funds will progress clinical programs and expand platform capabilities – SOUTH SAN FRANCISCO, Calif. , Feb. 15, 2024 /PRNewswir...
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to have ...
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations inter...
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 Fourth quarter reported diluted earnings per share ("EPS") of $1.70, up 95.4% from 2022; and adjusted diluted EPS of $2.15, up 8.6% from 2...
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
SECAUCUS, N.J. , Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORT...
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
BALTIMORE , Jan. 22, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research ...
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarte...
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J. , Jan. 17, 2024 /PRN...
Quest Diagnostics and Ultima Collaborate to Scale Ultima's Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
FREMONT, Calif & SECAUCUS, N.J.--(BUSINESS WIRE)--Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation's lea...
Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J. , Jan. 8, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's...
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
BALTIMORE , Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Hay...
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
SECAUCUS, N.J. , Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and...
Quest Diagnostics Names Yuri A. Fesko, M.D.
Seasoned healthcare executive and oncologist joins Executive Leadership Team SECAUCUS, N.J. , Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic i...
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J. , Dec. 19, 2023 /PRNewswire/ -- Quest Diagnostics...
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
BALTIMORE , Dec. 14, 2023 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncol...
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J. , Dec. 7, 2...
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year
SECAUCUS, N.J. , Dec. 6, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that for the seventh straight year it has ...